Millennium Management’s United Therapeutics UTHR Stock Holding History

Millennium Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$46.8M	Buy	+78,900	New	+$39.3M	0.02%	868
2025 Q4	–	Sell	-12,100	Closed	-$5.07M	–	6484
2025 Q3	$5.07M	Buy	+12,100	New	+$4.07M	﹤0.01%	3136
2025 Q1	–	Sell	-3,300	Closed	-$1.16M	–	6421
2024 Q4	$1.16M	Sell	3,300 -7,100	-68%	-$2.61M	﹤0.01%	4076
2024 Q3	$3.73M	Sell	10,400 -2,300	-18%	-$777K	﹤0.01%	3105
2024 Q2	$4.05M	Buy	+12,700	New	+$3.36M	﹤0.01%	2908
2021 Q2	–	Sell	-50,000	Closed	-$8.36M	–	7138
2021 Q1	$8.36M	Buy	+50,000	New	+$8.34M	0.01%	1987
2019 Q4	–	Sell	-10,000	Closed	-$797K	–	4660
2019 Q3	$797K	Buy	+10,000	New	+$805K	﹤0.01%	2979
2017 Q4	–	Sell	-7,500	Closed	-$879K	–	4096
2017 Q3	$879K	Buy	+7,500	New	+$958K	﹤0.01%	2584
2017 Q2	–	Sell	-15,000	Closed	-$2.03M	–	3889
2017 Q1	$2.03M	Buy	+15,000	New	+$2.27M	﹤0.01%	2005
2015 Q2	–	Sell	-1,500	Closed	-$259K	–	3873
2015 Q1	$259K	Buy	+1,500	New	+$229K	﹤0.01%	3137

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Millennium Management's UTHR Position: Q1 2026 in Review

Millennium Management increased its United Therapeutics (UTHR) stake by 139% in Q1 2026, buying an estimated $44.5M and bringing the position to 153,372 shares worth $90.9M. The position accounts for 0.04% of the portfolio, ranked #488.

Millennium Management first reported a position in UTHR in Q2 2013 and has held it in 50 quarters since. The position peaked at $141M in Q4 2022. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Millennium Management held 153,372 shares of United Therapeutics worth $90.9M as of Q1 2026.
Millennium Management bought 89,299 United Therapeutics shares in Q1 2026, an estimated $44.5M.
United Therapeutics made up 0.04% of Millennium Management's portfolio in Q1 2026, its #488 holding.
Millennium Management first reported a position in United Therapeutics in Q2 2013 and has held it in 50 quarters since.
Millennium Management's United Therapeutics position peaked at $141M in Q4 2022.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.